1stOncology™: Cancer Intelligence Service – Page 103 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

On January 7, 2026 Emergent BioSolutions Inc. (NYSE: EBS) reported that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The audio link for Emergent’s session may be accessed here and will be live for up to 30 days.

The Company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website.

(Press release, Emergent BioSolutions, JAN 7, 2026, View Source [SID1234661798])

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

On January 7, 2026 Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, reported that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th at 3:00 pm PT / 6:00 pm ET.

A live webcast of the presentation will be available through the investor relations section of the Company’s website at ir.discmedicine.com and an archived replay will be available after the event.

(Press release, Disc Medicine, JAN 7, 2026, View Source [SID1234661797])

Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

On January 7, 2026 Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that it will present at Biotech Showcase taking place in San Francisco, January 12-14, 2026.

During the event, members of Azitra’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s clinical development strategy, recent corporate achievements, and anticipated milestones.

Details are as follows:

Event:

Biotech Showcase 2026

Date & Time

Tuesday, January 13, 2026, 2:30 PM, PT

Location:

Hilton San Francisco Union Square, Yosemite C (Ballroom Level)

Presenter

Travis Whitfill, Chief Operating Officer

Registration:

https://informaconnect.com/biotech-showcase/registration-options/

(Press release, Azitra, JAN 7, 2026, View Source [SID1234661796])

Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference

On January 7, 2026 Artios Pharma Limited ("Artios"), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response ("DDR") in cancer, reported that it will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco from January 12 to 15, 2026.

Mike Andriole, Artios’ Chief Executive Officer, will highlight the company’s strategic priorities for its two differentiated, potential first-in-class clinical programs in cancers with high unmet need. The company’s ATR inhibitor, alnodesertib, selects for ATM-deficient patients whose tumors harbor high degrees of DNA replication stress where the program has generated responses across eight different tumor types in early clinical development. It is currently being evaluated in two Phase 2 expansion cohorts in colorectal and pancreatic cancers. The company is also initiating a randomized Phase 2 study of its potentially first-in-class DNA polymerase Theta (Polθ) inhibitor, ART6043, in patients with BRCA-mutant HER2-negative breast cancer who are eligible to receive a PARP inhibitor.

The presentation will take place on Thursday, January 15, at 07:30 am PST (10:30 am EST / 03:30 pm UTC) in the Elizabethan B room (2nd floor) at The Westin St. Francis, 335 Powell Street, San Francisco.

(Press release, Artios Pharma, JAN 7, 2026, View Source [SID1234661795])

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

On January 7, 2026 Amgen (NASDAQ:AMGN) reported it will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

(Press release, Amgen, JAN 7, 2026, View Source [SID1234661794])